Our Services
Medical Information
Helpful Resources
Published on: 5/6/2026
Platelet-rich plasma (PRP) therapy for age-related macular degeneration (AMD) uses growth factors from a patient's own blood to potentially slow retinal cell loss in dry AMD, stabilize abnormal blood vessels in wet AMD, and reduce inflammation. Early small studies show encouraging results, and because PRP is autologous, it carries a low risk of rejection and may complement standard treatments like anti-VEGF injections. However, standardized protocols, injection routes, patient selection criteria, and long-term safety data still require further research.
Key considerations include preparation methods, delivery technique, and individual eligibility—all of which influence outcomes. If you're experiencing vision changes such as blurred central vision, distorted lines, or dark spots, understanding your symptoms early is critical to protecting your sight. AMD progresses silently, and identifying warning signs promptly can open the door to more treatment options, including emerging therapies like PRP. Take a free, instant, online symptom check to better understand what may be causing your symptoms and confidently navigate your next steps with your eye care provider.
Reviewed for medical accuracy: 07/09/2026
Advances in regenerative medicine are offering new hope for people with degenerative eye conditions. One promising approach is platelet-rich plasma (PRP) therapy, which uses a patient's own platelets to deliver growth factors directly to damaged tissue. Although most research is still in early stages, PRP for macular degeneration and other retinal disorders is attracting attention from clinicians and researchers.
Platelet-rich plasma is made by drawing a small amount of a patient's blood and spinning it in a centrifuge. This concentrates the platelets, which are cell fragments rich in:
These proteins encourage healing by:
When injected or applied near damaged tissue, PRP may enhance the eye's natural repair mechanisms.
Macular degeneration is a leading cause of vision loss in people over 50. There are two main types:
Current treatments:
PRP for macular degeneration is being explored because:
Although larger clinical trials are needed, several small studies and case reports have investigated PRP in retinal diseases:
Key takeaways:
While PRP offers exciting potential, optimal eye health relies on multiple strategies:
If you experience any of the following, do not delay in speaking to a qualified eye care professional:
To better understand your symptoms and prepare for your appointment, you can start by using this free AI-powered symptom checker to get personalized insights in minutes.
PRP represents an innovative tool in the fight against vision-threatening diseases like macular degeneration. By harnessing the healing power of the patient's own platelets, clinicians hope to slow disease progression and improve quality of life. As research advances, standardized protocols and larger clinical trials will clarify where PRP fits within mainstream eye care.
This information is not a substitute for professional medical advice. If you have any symptoms or concerns about your vision, please speak to a doctor—especially if you experience sudden or severe changes.
(References)
* Merinopoulou I, Sfakianakis I, Koryllos A, Marangos N. Platelet-rich plasma in ophthalmology: current perspectives. Front Med (Lausanne). 2024 Jan 10;10:1311003. doi: 10.3389/fmed.2023.1311003. PMID: 38202581; PMCID: PMC10808460.
* Merinopoulou I, Theophanous M, Sfakianakis I. Platelet-Rich Plasma for Ocular Surface Diseases. J Clin Med. 2022 Aug 4;11(15):4519. doi: 10.3390/jcm11154519. PMID: 35928811; PMCID: PMC9368545.
* Turgut B, Turgut F. Platelet-Rich Plasma in Ophthalmology: Therapeutic Potential. Cureus. 2023 Feb 9;15(2):e34812. doi: 10.7759/cureus.34812. PMID: 36762397; PMCID: PMC9912782.
* Wang J, Lu W, Song W, Song C, Yang Y, Zhao M, Liu B. Efficacy and Safety of Autologous Platelet-Rich Plasma in the Treatment of Retinal Diseases: A Systematic Review. J Clin Med. 2023 Aug 23;12(17):5510. doi: 10.3390/jcm12175510. PMID: 37618991; PMCID: PMC10488423.
* Giannaccare G, Buzzi M, Fresina M, Scorolli L, Versura P. Platelet-rich plasma in the treatment of ocular surface diseases: a systematic review of the literature. Ther Adv Ophthalmol. 2021 May 27;13:25158414211021469. doi: 10.1177/25158414211021469. PMID: 34208039; PMCID: PMC8168282.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.